Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Arcus Biosciences Q3 2026 net loss narrows 5% to $128 million; revenues drop 65% to $9 million

By Public Technologies
  • Arcus Biosciences’ third-quarter 2026 net loss narrowed 5% to $128 million; revenues fell 65% to $9 million year-over-year.
  • Research and development expenses declined 17% year-over-year to $117 million, primarily due to lower late- and early-stage development activity.
  • Cash, cash equivalents and marketable securities totaled $694 million at September 30; funding including October’s equity financing supports operations into 2029.
  • Casdatifan’s Phase 3 PEAK-1 enrollment should finish within two to three months; the first-line PEAK-20 trial should begin by year-end 2026.
  • Full-year 2026 GAAP revenues are expected to total $70 million to $75 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001724521-26-000056), on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.